stockrowNewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
Follow NAMS
Alert me
NewAmsterdam Pharma Company N.V. (NAMS) P/S ratio
As of 5 November 2026, NewAmsterdam Pharma Company N.V. (NAMS) trades at a P/S ratio of 91.1×. Over the past ten years it has ranged from 0.0× (December 2023) to 641× (July 2026); the current reading is higher than 72% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 185× | 246.86% |
| FY2024 | 53.2× | 23.08% |
| FY2023 | 43.2× | — |
| FY2022 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 116× | (80.18%) |
| Jun 2026 | 587× | 240.05% |
| Mar 2026 | 173× | (6.47%) |
| Dec 2025 | 185× | 92.25% |
| 11 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| PHVS Pharvaris N.V. compare | n/m |
| MBX MBX Biosciences, Inc. compare | n/m |
| ADMA ADMA Biologics Inc compare | 5.7× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 5.7× |
| XNCR Xencor, Inc. compare | 24.8× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 27.9× |
| PVLA Palvella Therapeutics, Inc. compare | 54.1× |
| NAMS NewAmsterdam Pharma Company N.V. | 91.1× |
| CLDX Celldex Therapeutics, Inc. compare | 2,498× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on NAMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement